Electrophysiological profiling of Axiogenesis vCor.4U iPSC-derived cardiomyocytes

Poster Description

Here, we have assessed the suitability of Axiogenesis CorV.4U 2nd generation iPSC-CM for cardiotoxicity screening by evaluating their biophysical and pharmacological characteristics using three different methodologies:

  1. Whole-cell voltage clamp recordings to quantify inward Na+ and Ca2+ currents (INa and ICa), as well as outward and inward K+ currents (IK).
  2. Current clamp measurements of action potential (AP) parameters and pharmacology. Representative compounds from the CiPA validation toolbox in addition to compounds discriminating between atrial and ventricular phenotypes, were utilised in these experiments. These data confirmed the functional expression and pharmacology of typical cardiac currents, including INa, ICa, and IKr.
  3. Phenotypic measurements of impedance (contraction) and extracellular field potential (excitability) were made on the xCELLigence RTCA CardioECR platform.
Download
Recommended Publications
Latest Publications
Development of Automated Electrophysiology Assays for the Characterisation of Inhibitors Against Human HCN Ion Channels

We demonstrate the generation and validation of a stable CHO-hHCN2 cell line used as a cellular tool in the successful development of hHCN2 automated electrophysiology screening assays.

Development of a High-Throughput Automated Electrophysiology Assay for Human Nav1.9 Inhibitor Screening

We have developed a robust high-throughput automated electrophysiology assay using a monoclonal CHO-hNav1.9 cellular reagent suitable for fully supporting a Nav1.9 discovery program.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram